Combining Endocrine Agents With Chemotherapy : Which Patients and What Sequence?PRITCHARD, Kathleen I.Cancer. 2008, Vol 112, Num 3, pp 718-722, issn 0008-543X, 5 p., SUPConference Paper

Should tamoxifen be used to treat premenopausal women with breast cancer?PRITCHARD, Kathleen I.Cancer investigation. 2000, Vol 18, Num 7, pp 685-686, issn 0735-7907Article

Therapeutic advantages of droloxifene, a new antiestrogen, in breast cancer, Hamburg FRG, August 18, 1990PRITCHARD, Kathleen I; ROCHEFORT, Henri.American journal of clinical oncology. 1991, Vol 14, issn 0277-3732, 70 p., SUP2Conference Proceedings

Droloxifene-induced spikes of tumor markers predict benefit of therapyKREIENBERG, R.American journal of clinical oncology. 1991, Vol 14, pp S56-S61, issn 0277-3732, SUP2Conference Paper

Droloxifene, a new antiestrogen, in advanced breast cancer : a double-blind dose-finding studyDESCHENES, L.American journal of clinical oncology. 1991, Vol 14, pp S52-S55, issn 0277-3732, SUP2Conference Paper

Mechanism of action of high-affinity antiestrogens : an overviewROCHEFORT, H.American journal of clinical oncology. 1991, Vol 14, pp S1-S4, issn 0277-3732, SUP2Conference Paper

Cardiovascular health and aromatase inhibitorsPRITCHARD, Kathleen I; ABRAMSON, Beth L.Drugs (Basel). 2006, Vol 66, Num 13, pp 1727-1740, issn 0012-6667, 14 p.Article

Droloxifene, a new antiestrogen : hormonal influences in postmenopausal breast cancer patientsKVINNSLAND, S.American journal of clinical oncology. 1991, Vol 14, pp S46-S51, issn 0277-3732, SUP2Conference Paper

Japanese early phase II study of droloxifene in the treatment of advanced breast cancer : preliminary dose-finding studyABE, O.American journal of clinical oncology. 1991, Vol 14, pp S40-S45, issn 0277-3732, SUP2Conference Paper

Structural requirements for the in vitro transformation of Syrian hamster embryo cells by stilbene estrogens and triphenylethylene-type antiestrogensMETZLER, M; SCHIFFMANN, D.American journal of clinical oncology. 1991, Vol 14, pp S30-S35, issn 0277-3732, SUP2Conference Paper

Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancerDENT, Susan F; GASPO, Rania; KISSNER, Michelle et al.Breast cancer research and treatment. 2011, Vol 126, Num 2, pp 295-310, issn 0167-6806, 16 p.Article

European early phase II dose-finding study of droloxifene in advanced breast cancerBELLMUNT, J; SOLE, L.American journal of clinical oncology. 1991, Vol 14, pp S36-S39, issn 0277-3732, SUP2Conference Paper

Pharmacokinetics of droloxifene and its metabolites in breast cancer patientsGRILL, H. J; POLLOW, K.American journal of clinical oncology. 1991, Vol 14, pp S21-S29, issn 0277-3732, SUP2Conference Paper

Managing patients on endocrine therapy : Focus on quality-of-life issuesWHELAN, Timothy J; PRITCHARD, Kathleen I.Clinical cancer research. 2006, Vol 12, Num 3, issn 1078-0432, 1056s-1060s, 2Conference Paper

Pharmacologic and biologic properties of droloxifene, a new antiestrogenEPPENBERGER, U; WOSIKOWSKI, K; KÜNG, W et al.American journal of clinical oncology. 1991, Vol 14, pp S5-S14, issn 0277-3732, SUP2Conference Paper

Prognostic Effects of 25-Hydroxyvitamin D Levels in Early Breast CancerGOODWIN, Pamela J; ENNIS, Marguerite; PRITCHARD, Kathleen I et al.Journal of clinical oncology. 2009, Vol 27, Num 23, pp 3757-3763, issn 0732-183X, 7 p.Article

HER2/neu in systemic therapy for women with breast cancer : a systematic reviewDHESY-THIND, Bindi; PRITCHARD, Kathleen I; MESSERSMITH, Hans et al.Breast cancer research and treatment. 2008, Vol 109, Num 2, pp 209-229, issn 0167-6806, 21 p.Article

Chromosome 17 centromere (CEP17) duplication as a predictor of anthracycline response: evidence from the NCIC Clinical Trials Group (NCIC CTG) MA.5 TrialPRITCHARD, Kathleen I; MUNRO, Alison; O'MALLEY, Frances P et al.Breast cancer research and treatment. 2012, Vol 131, Num 2, pp 541-551, issn 0167-6806, 11 p.Article

Evaluating Survivorship Care Plans: Results of a Randomized, Clinical Trial of Patients With Breast CancerGRUNFELD, Eva; JULIAN, Jim A; PORTER, Geoffrey A et al.Journal of clinical oncology. 2011, Vol 29, Num 36, pp 4755-4762, issn 0732-183X, 8 p.Article

Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trialALBAIN, Kathy S; BARLOW, William E; LICHTER, Allen S et al.Lancet (British edition). 2010, Vol 374, Num 9707, pp 2055-2063, issn 0140-6736, 9 p.Article

Genome-Wide Associations and Functional Genomic Studies of Musculoskeletal Adverse Events in Women Receiving Aromatase InhibitorsINGLE, James N; SCHAID, Daniel J; PATER, Joseph et al.Journal of clinical oncology. 2010, Vol 28, Num 31, pp 4674-4682, issn 0732-183X, 9 p.Article

HER-2 and Topoisomerase II As Predictors of Response to ChemotherapyPRITCHARD, Kathleen I; MESSERSMITH, Hans; ELAVATHIL, Leela et al.Journal of clinical oncology. 2008, Vol 26, Num 5, pp 736-744, issn 0732-183X, 9 p.Article

Fasting insulin and outcome in early-stage breast cancer: Results of a prospective cohort studyGOODWIN, Pamela J; ENNIS, Marguerite; PRITCHARD, Kathleen I et al.Journal of clinical oncology. 2002, Vol 20, Num 1, pp 42-51, issn 0732-183XArticle

Induction of transforming growth factor β by the antiestrogens droloxifene, tamoxifen, and toremifene in MCF-7 cellsKNABBE, C; ZUGMAIER, G; SCHMAHL, M et al.American journal of clinical oncology. 1991, Vol 14, pp S15-S20, issn 0277-3732, SUP2Conference Paper

Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27—A Randomized Controlled Phase III TrialGOSS, Paul E; INGLE, James N; D'SOUZA, David P et al.Journal of clinical oncology. 2013, Vol 31, Num 11, pp 1398-1404, issn 0732-183X, 7 p.Article